Clarient launches KRAS colorectal cancer testing service in US
This article was originally published in Clinica
Executive Summary
Clarient has launched its KRAS genetic test for colorectal cancer. The services lab performs all testing at its site in Aliso Viejo, California so mainly caters for the US market, but also receives international samples "on a routine basis". Mutations in KRAS are associated with a poor response in patients treated with the EGFR inhibitors Vectibix, developed by Amgen, and Merck KGaA's Erbitux. Around 40-45% patients harbour the mutations, meaning the KRAS protein, which is downstream of the EGFR receptor, is always "turned on" regardless of whether EGFR is inhibited. Manchester, UK-based DxS also markets a KRAS test, TheraScreen K-RAS, which is CE marked for sale in Europe and was recently launched in Australia. However, DxS's test is not yet cleared by the US FDA.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.